Pulsehaler™ – Breakthrough Treatment for COPD
Respinova has developed a new device for the treatment of COPD. COPD is the 3rd most fatal of all diseases affecting over 350 million people worldwide. Respinova’s Pulsehaler™ technology is the first and only treatment to directly open the small airways, thereby reducing breathlessness and improving patient’s ability to walk.
The patented Pulsehaler™ technology was clinically proven in a study at Hadassah Hospital in Israel, and published in the peer reviewed Journal of COPD. Respinova recently received a prestigious $2.7MM Horizon 2020 Phase II grant from the EU, which recognized the uniqueness of our solution and its commercial potential.
Respinova is seeking distribution partners in Europe and the USA as well as selected other markets.